About Instituto de Ensino E Pesquisa Sao Lucas
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Janssen Research & Development, LLC
9
Hoffmann-La Roche
7
Bayer
2
Bristol-Myers Squibb
1
Celgene
1
Eli Lilly and Company
1
Kartos Therapeutics, Inc.
1
Pfizer
1
Sumitomo Pharma Oncology, Inc.
1
Takeda
1
Clinical Trials at Instituto de Ensino E Pesquisa Sao Lucas
During the past decade, Instituto de Ensino E Pesquisa Sao Lucas conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 12 clinical trials were completed, i.e. on
average, 70.6% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 6 clinical trials were completed. i.e. 120%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)
2009-10-13
2018-05-09
Completed
450
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
2011-07-26
2018-01-31
Terminated
1,418
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
2011-12-20
2018-06-02
Completed
692
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
2013-04-03
2025-04-03
Active, not recruiting
1,487
A Long-term Extension Study of PCI-32765 (Ibrutinib)
2013-09-09
2027-01-29
Enrolling by invitation
700
A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia
2013-11-04
2018-10-08
Completed
979
A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer
2014-10-01
2017-09-20
Completed
714
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
2014-12-31
2025-08-31
Active, not recruiting
445
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Instituto de Ensino E Pesquisa Sao Lucas" #1 sponsor was "Janssen Research & Development, LLC" with 9 trials, followed by "Hoffmann-La Roche" with 7 trials
sponsored, "Bayer" with 2 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored and "Celgene"
with 1 trials sponsored. Other sponsors include 0 different institutions and
companies that sponsored additional 10 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto de Ensino E Pesquisa Sao Lucas"
#1 collaborator was "Pharmacyclics LLC." with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Fondazione Italiana Linfomi ONLUS" with 1 trials as a collaborator, "German Breast Group" with 1 trials as a collaborator and "German CLL Study Group" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were
collaborators in the rest 9 trials.
Clinical Trials Conditions at Instituto de Ensino E Pesquisa Sao Lucas
According to Clinical.Site data, the most researched conditions in "Instituto de Ensino E Pesquisa Sao Lucas" are
"Multiple Myeloma" (3 trials), "Chronic Lymphocytic Leukemia" (2 trials), "B-Cell Chronic Lymphocytic Leukemia" (1 trials), "BRAF V600E-mutant Metastatic Colorectal Cancer" (1 trials) and "Breast Cancer" (1 trials). Many other conditions were trialed in "Instituto de Ensino E Pesquisa Sao Lucas" in a lesser frequency.
Clinical Trials Intervention Types at Instituto de Ensino E Pesquisa Sao Lucas
Most popular intervention types in "Instituto de Ensino E Pesquisa Sao Lucas" are "Drug" (24 trials) and "Other" (2 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (4 trials), "Prednisone" (4 trials), "Rituximab" (4 trials), "Chlorambucil" (3 trials) and "Cyclophosphamide" (3 trials). Other intervention names were less common.
Clinical Trials Genders at Instituto de Ensino E Pesquisa Sao Lucas
The vast majority of trials in "Instituto de Ensino E Pesquisa Sao Lucas" are
21 trials for "All" genders and 4 trials for "Male" genders.
Clinical Trials Status at Instituto de Ensino E Pesquisa Sao Lucas
Currently, there are NaN active trials in "Instituto de Ensino E Pesquisa Sao Lucas".
undefined are not yet recruiting,
6 are recruiting,
6 are Active, not recruiting,
and 1 are Enrolling by invitation.
In total, there were 9 completed trials in Instituto de Ensino E Pesquisa Sao Lucas,
undefined suspended trials,
and 3 terminated clinical trials to date.
Out of the total trials that were conducted in Instituto de Ensino E Pesquisa Sao Lucas, 1 "Phase 1"
clinical trials were conducted, 6 "Phase 2" clinical
trials and 20 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".